A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis

Journal of Infectious Diseases

Volumn 208, Issue 8, 2013, Pages 1342-1348

  Castellanos Gonzalez, Alejandro ^a   White, A Clinton ^a   Ojo, Kayode K ^b   Vidadala, Rama S R ^c   Zhang, Zhongsheng ^d   Reid, Molly C ^b   Fox, Anna M W ^b   Keyloun, Katelyn R ^b   Rivas, Kasey ^b   Irani, Ayesha ^a   Dann, Sara M ^a   Fan, Erkang ^d   Maly, Dustin J ^c   Van Voorhis, Wesley C ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Division of Allergy and Infectious Disease   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

antiparasitic; bumped kinase inhibitor; Calcium dependant Protein kinase; CpCDPK 1; cryptosporidiosis; Cryptosporidium parvum

Indexed keywords

BUMPED KINASE INHIBITOR; CALCIUM DEPENDENT PROTEIN KINASE INHIBITOR 1294; PLACEBO; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DNA EXTRACTION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SPOROZOITE;

ANTIPARASITIC; BUMPED KINASE INHIBITOR; CALCIUM-DEPENDANT PROTEIN KINASE; CPCDPK-1; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM;

ANIMALS; ANTIPROTOZOAL AGENTS; APOPTOSIS; CELL LINE; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; GENES, PROTOZOAN; HUMANS; INTESTINES; MICE; MICE, SCID; PARASITE LOAD; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTOZOAN PROTEINS;

EID: 84885026864     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit327     Document Type: Article

References (21)

1. White AC, Jr. Cryptosporidium species. In: Mandell GL, Bennett JE, Dolin R (eds): Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Churchill-Livingstone/ Elsevier, 2010:3547-3560.
2. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): A prospective, case-control study. Lancet 2013; 382:209-22.
3. Shirley DA, Moonah SN, Kotloff KL. Burden of disease from cryptosporidiosis. Curr Opin Infect Dis 2012; 25:555-63.
4. Lima AAM, Samie A, Guerrant RL. Cryptosporidiosis. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases. Principles, pathogens, and practice. Philadelphia: Elsevier-Churchill Livingston, 2011:640-63.
5. Cabada MM, White AC Jr. Treatment of cryptosporidiosis: Do we know what we think we know? Curr Opin Infect Dis 2010; 23:494-9.
6. Rossignol JF. Cryptosporidium and Giardia: Treatment options and prospects for new drugs. Exp Parasitol 2010; 124:45-53.
7. Theodos CM, Griffiths JK, D'Onfro J, Fairfield A, Tzipori S. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob Agents Chemother 1998; 42:1959-65.
8. Healey MC, Yang S, Rasmussen KR, Jackson MK, Du C. Therapeutic efficacy of paromomycin in immunosuppressed adult mice infected with Cryptosporidium parvum. J Parasitol 1995; 81:114-6.
9. Hashmey R, Smith NH, Cron S, Graviss EA, Chappell CL, White AC Jr. Cryptosporidiosis in Houston, Texas. A report of 95 cases. Medicine (Baltimore) 1997; 76:118-39.
10. Nagamune K, Sibley LD. Comparative genomic and phylogenetic analyses of calcium ATPases and calcium-regulated proteins in the apicomplexa. Mol Biol Evol 2006; 23:1613-27.
11. Kisaburo Nagamune SNM, Chini EN, Sibley LD. Calcium regulation and signaling in apicomplexan parasites. New York: Springer, 2008: 70-81.
12. Murphy RC, Ojo KK, Larson ET, et al. Discovery of potent and selective inhibitors of calcium-dependent protein kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med Chem Lett 2010; 1:331-5.
13. Ojo KK, Larson ET, Keyloun KR, et al. Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat Struct Mol Biol 2010; 17:602-7.
14. Johnson SM, Murphy RC, Geiger JA, et al. Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. J Med Chem 2012; 55:2416-26.
15. Takeuchi D, Jones VC, Kobayashi M, Suzuki F. Cooperative role of macrophages and neutrophils in host antiprotozoan resistance in mice acutely infected with Cryptosporidium parvum. Infect Immun 2008; 76:3657-63.
16. Pagel JM, Laugen C, Bonham L, et al. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas. Clin Cancer Res 2005; 11:4857-66.
17. Ojo KK, Pfander C, Mueller NR, et al. Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors. J Clin Invest 2012; 122:2301-5.
18. Larson ET, Ojo KK, Murphy RC, et al. Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. J Med Chem 2012; 55:2803-10.
19. Tzipori S, Widmer G. Animal models. Cryptosporidium and cryptosporidiosis. Boca Raton: CRC Press, 2008.
20. Costa LB, Noronha FJ, Roche JK, et al. Novel in vitro and in vivo models and potential new therapeutics to break the vicious cycle of Cryptosporidium infection and malnutrition. J Infect Dis 2012; 205:1464-71.
21. Sasahara T, Maruyama H, Aoki M, et al. Apoptosis of intestinal crypt epithelium after Cryptosporidium parvum infection. J Infect Chemother 2003; 9:278-81.